The Efficiency and Toxicity of Anlotinib in Combination with Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen As Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study
Clinical breast cancer(2024)
Key words
Triple Negative Breast Cancer,Neoadjuvant Therapy,Anti-angiogenesis
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined